Pro-inflammatory autoreactive T lymphocytes specific for cartilage-associated antigens play a pivotal role in the development of rheumatoid arthritis. Standard treatment of rheumatoid arthritis is based on nonsteroidal anti-inflammatory drugs (NSAIDs), nonbiologic and biologic disease-modifying antirheumatic drugs (DMARDs) and non-specific (non-selective) immunosuppressants (hormones, cytostatic agents and others). This treatment fails to interrupt the underlying immunopathological events and is often associated with serious complications.
T-cell autovaccination-based technology is aimed to stimulate patient’s immune responses, which selectively inactivate pathogenic self-reactive Т lymphocytes.
Forty-two patients (age 28–58 y; 37 women, 5 men) with rheumatoid arthritis (disease history ≥2 years) were subjected to the T-cell vaccination treatment. Our clinical data (Table 1) showed that T cell vaccination of rheumatoid arthritis patients (n = 42) resulted in apparent clinical improvements over a 2 year follow-up .
Table 1. Clinical parameters of rheumatoid arthritis patients.
|Parameter||Follow-up time (months)|
|0 (n=42)||3 (n=42)||6 (n=42)||12 (n=42)||18 (n=32)||24 (n=22)|
In conclusion. rheumatoid arthritis patients with early and advanced stages of the disease can obtain significant clinical benefits due to the application of autologous T cell vaccination.